Found 4 Thrombocytopenia and Thrombocytopenia Prevention trials

A listing of Thrombocytopenia and Thrombocytopenia Prevention medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

A phase 3, randomized, double-blind study of ianalumab (VAY736) versus placebo in addition to first-line corticosteroids in primary immune thrombocytopenia

99 or below

All genders

To demonstrate that the addition of ianalumab to standard first-line corticosteroids prolongs Time to Treatment Failure compared to Corticosteroids alone in participants with primary ITP. ITP means immune thrombocytopenia. Time from randomization to treatment failure which is defined as Platelet count below 30G/L after 8 weeks from randomization. Need for …

Learn More

A phase 2 study of ianalumab (VAY736) in patients with primary immune thrombocytopenia (ITP) previously treated with at least two lines of therapies

99 or below

All genders

PURPOSE To evaluate the efficacy of ianalumab (i.e., platelet response 50 G/L) in participants with primary ITP previously treated with at least a corticosteroid and a TPO-RA. A platelet count of 50 G/L at two (or more) consecutive assessments at least 7 days apart between Week 1 Day 1 and …

Learn More

A phase 3, randomized, double-blind, study of ianalumab (VAY736) versus placebo in addition to eltrombopag in primary immune thrombocytopenia (ITP) patients who failed steroids

99 or below

All genders

PURPOSE The overall objective is to demonstrate that the addition of ianalumab (either 3mg/kg or 9mg/kg dosage) to standard care (eltrombopag) is more effective and safer compared to the standard of care (eltrombopag) alone. Primary outcome variable is determined by the time to treatment failure which is in turn determined …

Learn More

Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipients

99 or below

All genders

Please refer to protocol section 3 for information on study objectives. Overall objectives include: Objective 1: Determine the efficacy of letermovir for preventing CMV infection in thoracic organ transplant recipients as compared to valganciclovir prophylaxis Objective 2: Determine the tolerability of letermovir for CMV prophylaxis among heart and lung transplant …

Learn More